Corinne Jenkins

Shares of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) jumped in early trading on Monday, after remaining broadly flat last week. Investor concerns around the possible failure of the ongoing Phase III PHOENIX study appear to be “overdone,” according to Goldman Sachs. The Amylyx...

Gritstone bio Inc (NASDAQ: GRTS) has insufficient cash either to reach de-risking catalysts for its lead oncology program, GRANITE, or to support the clinical development of its second program, SLATE, beyond early data, according to Goldman Sachs. The Gritstone bio Analyst: Corinne Jenkins...

The initial phase II data in patients with hypothalamic obesity (HO) has transformed the opportunity for Rhythm Pharmaceuticals Inc’s (NASDAQ: RYTM) Imcivree, according to Goldman Sachs. The Rhythm Pharmaceuticals Analyst: Corinne Jenkins upgraded Rhythm Pharmaceuticals from Neutral to Buy...